Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-08 am EST
99.30 CHF   +0.10%
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Deport Walmart...
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medacta : 2022 Half-Year Report

09/09/2022 | 01:10am EST

H A L F - Y E A R R E P O R T 2 0 2 2

2

MEDACTA AT A GLANCE

Medacta is an international company specializing in the design, production, and distribution of innovative orthopedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

3

From minimally invasive surgery to

Personalized Medicine and beyond

4

TABLE OF CONTENTS

3

MEDACTA AT A GLANCE

HALF-YEAR 2022 KEY FINANCIAL FIGURES

6

HIGHLIGHTS FIRST HALF 2022

7

SHARE INFORMATION

8

LETTER TO SHAREHOLDERS

10

ALTERNATIVE PERFORMANCE MEASURES

12

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022

17

1.

INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS FOR THE PERIODS ENDED JUNE 30, 2022 AND 2021

18

2.

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIODS ENDED JUNE 30, 2022 AND 2021

19

3.

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE PERIODS ENDED JUNE 30, 2022 AND DECEMBER 31, 2021

20

4.

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIODS ENDED JUNE 30, 2022 AND 2021

21

5.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIODS ENDED JUNE 30, 2022 AND 2021

22

6.

SELECTED EXPLANATORY NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

23

7.

INDEPENDENT AUDITOR'S REPORT

33

INVESTOR CALENDAR

34

CONTACTS

34

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Medacta Group SA published this content on 09 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2022 05:09:03 UTC.


ę Publicnow 2022
All news about MEDACTA GROUP SA
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Depo..
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
11/06Medacta Says First US Hip Surgery Carried Out With Double Mobility Converter
MT
11/04Medacta Group Sa : Medacta Expands its Hip Offerings with New Cobalt-Free SensiTiN™ ..
EQ
10/12Medacta NextAR Spine wins the 2022 Spine Technology Award from Orthopedics This Week du..
EQ
10/05Medacta's MySpine Anchor Technology Used in First US Procedure
MT
10/05Medacta announces the first MySpine Anchor procedure completed in the US
EQ
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 429 M 452 M 452 M
Net income 2022 56,2 M 59,2 M 59,2 M
Net Debt 2022 123 M 130 M 130 M
P/E ratio 2022 35,7x
Yield 2022 0,59%
Capitalization 2 011 M 2 121 M 2 121 M
EV / Sales 2022 4,98x
EV / Sales 2023 4,35x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 100,66 €
Average target price 107,65 €
Spread / Average Target 6,95%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-30.14%2 109
ABBOTT LABORATORIES-25.53%182 744
MEDTRONIC PLC-25.49%102 304
BECTON, DICKINSON AND COMPANY0.29%69 846
DEXCOM, INC.-12.97%45 544
HOYA CORPORATION-21.30%35 092